IL159905A0 - Enantioselective synthesis of ceramide-like compounds, novel intermediates, their preparation and pyrrole derivatives - Google Patents

Enantioselective synthesis of ceramide-like compounds, novel intermediates, their preparation and pyrrole derivatives

Info

Publication number
IL159905A0
IL159905A0 IL15990502A IL15990502A IL159905A0 IL 159905 A0 IL159905 A0 IL 159905A0 IL 15990502 A IL15990502 A IL 15990502A IL 15990502 A IL15990502 A IL 15990502A IL 159905 A0 IL159905 A0 IL 159905A0
Authority
IL
Israel
Prior art keywords
ceramide
compounds
preparation
novel intermediates
pyrrole derivatives
Prior art date
Application number
IL15990502A
Other languages
English (en)
Original Assignee
Genzyme Corp
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23182463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL159905(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Univ Michigan filed Critical Genzyme Corp
Publication of IL159905A0 publication Critical patent/IL159905A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
IL15990502A 2001-07-16 2002-07-16 Enantioselective synthesis of ceramide-like compounds, novel intermediates, their preparation and pyrrole derivatives IL159905A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30581401P 2001-07-16 2001-07-16
PCT/US2002/022659 WO2003008399A1 (en) 2001-07-16 2002-07-16 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors

Publications (1)

Publication Number Publication Date
IL159905A0 true IL159905A0 (en) 2004-06-20

Family

ID=23182463

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15990502A IL159905A0 (en) 2001-07-16 2002-07-16 Enantioselective synthesis of ceramide-like compounds, novel intermediates, their preparation and pyrrole derivatives
IL159905A IL159905A (en) 2001-07-16 2004-01-16 Antibiotic synthesis of ceramide image compound, intermediate, preparation and pyrolysis history
IL193244A IL193244A0 (en) 2001-07-16 2008-08-05 Amine derivatives useul for the synthesis of ceramide-like compounds and methods utilizing the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL159905A IL159905A (en) 2001-07-16 2004-01-16 Antibiotic synthesis of ceramide image compound, intermediate, preparation and pyrolysis history
IL193244A IL193244A0 (en) 2001-07-16 2008-08-05 Amine derivatives useul for the synthesis of ceramide-like compounds and methods utilizing the same

Country Status (15)

Country Link
US (11) US6855830B2 (enExample)
EP (3) EP2266968B1 (enExample)
JP (6) JP5038582B2 (enExample)
AT (2) ATE554082T1 (enExample)
BE (1) BE2015C029I2 (enExample)
BR (3) BR122015016313B8 (enExample)
CA (1) CA2453978C (enExample)
CY (1) CY2015028I1 (enExample)
DK (3) DK2067775T3 (enExample)
ES (3) ES2395122T3 (enExample)
FR (1) FR15C0036I2 (enExample)
IL (3) IL159905A0 (enExample)
LU (1) LU92717I2 (enExample)
PT (3) PT2067775E (enExample)
WO (1) WO2003008399A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384719A1 (en) * 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1358172B1 (en) 2001-01-10 2009-11-18 The Regents of The University of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US6855830B2 (en) 2001-07-16 2005-02-15 Genzyme Corporation Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
WO2003045928A1 (en) * 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
JP4195411B2 (ja) * 2004-04-12 2008-12-10 セイコーエプソン株式会社 有機エレクトロルミネッセンス装置の製造方法
BRPI0517701A8 (pt) * 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
PL383715A1 (pl) * 2005-01-26 2008-05-12 Allergan, Inc. Amidy kwasu 3-arylo-3-hydroksy-2-amino-propionowego, amidy kwasu 3-heteroarylo-3-hydroksy-2-amino-propionowego i ich związki pokrewne posiadające aktywność przeciwbólową i/lub pobudzającą odporność
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
CN102978185B (zh) 2007-01-18 2015-02-11 建新公司 包含氨基氧基基团的寡糖及其轭合物
US8173683B2 (en) 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
WO2008109610A1 (en) * 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
US20140179925A1 (en) 2009-09-04 2014-06-26 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
EP2594565B1 (en) 2007-05-31 2018-10-24 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
KR101640263B1 (ko) 2007-10-05 2016-07-15 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
JP2011529500A (ja) * 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
CN102271678B (zh) * 2008-10-03 2017-06-30 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合成酶抑制剂
EP3608330B1 (en) 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
MY192644A (en) * 2009-11-27 2022-08-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
EP3236686A1 (en) 2010-04-16 2017-10-25 Kyocera Corporation Radio communication system, high-power base station, low-power base station, and communication control method
SG10201605874TA (en) 2011-04-22 2016-09-29 Genzyme Corp Modified acid alpha glucosidase with accelerated processing
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2014150043A1 (en) * 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
CN110372636B (zh) 2013-09-20 2023-03-28 生物马林药物股份有限公司 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
WO2015059679A1 (en) * 2013-10-25 2015-04-30 Dr. Reddy's Laboratories Limited Improved process for the preparation of eliglustat
EP3063141B1 (en) 2013-10-29 2018-02-28 BioMarin Pharmaceutical Inc. N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
ES2856898T3 (es) 2015-02-02 2021-09-28 Univ Michigan Regents Inhibidores de glucosilceramida sintasa y métodos terapéuticos que usan los mismos
CN104557851B (zh) * 2015-02-10 2017-04-05 苏州明锐医药科技有限公司 依鲁司他的制备方法
EP3283483B1 (en) 2015-04-14 2018-12-19 Sandoz AG Crystalline eliglustat hydrochloride
WO2017068496A1 (en) * 2015-10-20 2017-04-27 Dr. Reddy' S Laboratories Limited Improved process for the preparation of eliglustat and its salts
CN105646442A (zh) * 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 一种依利格鲁司他的制备方法
US20190142782A1 (en) 2016-04-11 2019-05-16 Spedding Research Solutions Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
CN106967042B (zh) * 2017-03-21 2020-08-14 浙江奥翔药业股份有限公司 依利格鲁司他的合成方法及其中间体化合物
CN108822072B (zh) * 2017-04-11 2021-01-12 中国医学科学院药物研究所 一种制备伊力格鲁司他的方法
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2018225085A1 (en) 2017-06-05 2018-12-13 Cipla Limited Stable solid dispersions of eliglustat hemitartrate
IL275091B2 (en) 2017-12-15 2024-09-01 Genzyme Corp Methods for treating gaucher disease
WO2019123476A1 (en) 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
CN111217791B (zh) * 2018-11-27 2024-02-02 广东东阳光药业股份有限公司 依鲁司他中间体及其制备方法
US12398114B2 (en) 2019-03-22 2025-08-26 Piramal Pharma Limited Process for the preparation of ELIGLUSTAT and its intermediate
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
US11220479B2 (en) 2019-10-23 2022-01-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2021214771A1 (en) 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases
WO2021221953A1 (en) 2020-04-28 2021-11-04 The Regents Of The University Of Michigan Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
CN116120274A (zh) 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses
WO2026006099A1 (en) 2024-06-24 2026-01-02 Genzyme Corporation Eliglustat for the treatment of gaucher disease
EP4725474A1 (en) 2024-10-11 2026-04-15 Genepharm S.A. A solid composition of eliglustat

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
JPH0416856A (ja) 1990-05-10 1992-01-21 Canon Inc 正帯電性非磁性トナー
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
CN1128951A (zh) * 1993-08-13 1996-08-14 生化学工业株式会社 治疗神经元疾病的药物
ES2149350T3 (es) 1994-02-02 2000-11-01 Liposome Co Inc Compuestos y liposomas farmaceuticamente activos y metodos para su utilizacion.
CA2192555C (en) * 1994-06-10 2005-01-11 Jinichi Inokuchi 2-acylaminopropanol compound and medicinal composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) * 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5916911A (en) * 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) * 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5916802A (en) * 1997-02-19 1999-06-29 Fritz Berthold Device for measuring ATP
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6511979B1 (en) 1998-07-27 2003-01-28 Johns Hopkins University Methods for treating conditions modulated by lactosylceramide
EP1384719A1 (en) 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
EP1358172B1 (en) 2001-01-10 2009-11-18 The Regents of The University of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) * 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
US6855830B2 (en) 2001-07-16 2005-02-15 Genzyme Corporation Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
ES2546181T3 (es) * 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos

Also Published As

Publication number Publication date
PT2067775E (pt) 2012-07-16
EP1409467A1 (en) 2004-04-21
US7763738B2 (en) 2010-07-27
BR0211379A (pt) 2004-08-17
JP5227348B2 (ja) 2013-07-03
ES2395122T3 (es) 2013-02-08
ES2399323T3 (es) 2013-03-27
DK2067775T3 (da) 2012-07-16
EP2266968A3 (en) 2011-05-18
JP2017075151A (ja) 2017-04-20
JP2005502635A (ja) 2005-01-27
US20050222244A1 (en) 2005-10-06
JP2010095546A (ja) 2010-04-30
CY2015028I2 (el) 2016-07-27
HK1132267A1 (en) 2010-02-19
EP2266968B1 (en) 2013-01-09
ATE555102T1 (de) 2012-05-15
US8779163B2 (en) 2014-07-15
JP6182254B2 (ja) 2017-08-16
JP2005255686A (ja) 2005-09-22
US20170334888A1 (en) 2017-11-23
ES2395463T4 (es) 2013-02-12
CA2453978A1 (en) 2003-01-30
JP4708073B2 (ja) 2011-06-22
WO2003008399A1 (en) 2003-01-30
CA2453978C (en) 2011-10-11
US7615573B2 (en) 2009-11-10
US20080058514A1 (en) 2008-03-06
US6855830B2 (en) 2005-02-15
BR122015016314B1 (pt) 2019-04-16
BR122015016313B1 (pt) 2019-04-16
US7265228B2 (en) 2007-09-04
US7196205B2 (en) 2007-03-27
FR15C0036I1 (enExample) 2015-06-26
EP2067775A1 (en) 2009-06-10
US9546161B2 (en) 2017-01-17
PT2266968E (pt) 2013-02-25
US20110003987A1 (en) 2011-01-06
HK1153733A1 (en) 2012-04-05
IL159905A (en) 2009-05-04
US20120296088A1 (en) 2012-11-22
US8138353B2 (en) 2012-03-20
DK2266968T3 (da) 2013-04-08
EP1409467B1 (en) 2012-04-18
US20070203223A1 (en) 2007-08-30
US20150148534A1 (en) 2015-05-28
US20030050299A1 (en) 2003-03-13
JP5038582B2 (ja) 2012-10-03
US20210171507A1 (en) 2021-06-10
EP2266968A2 (en) 2010-12-29
EP2067775B1 (en) 2012-04-25
FR15C0036I2 (fr) 2016-05-27
ATE554082T1 (de) 2012-05-15
IL193244A0 (en) 2009-02-11
JP2015180656A (ja) 2015-10-15
BR122015016314B8 (pt) 2021-05-25
BRPI0211379B8 (pt) 2021-05-25
BR122015016313B8 (pt) 2021-05-25
CY2015028I1 (el) 2016-07-27
ES2395463T3 (es) 2013-02-15
US20050009872A1 (en) 2005-01-13
US20190322649A1 (en) 2019-10-24
BE2015C029I2 (enExample) 2021-07-19
JP2013136618A (ja) 2013-07-11
LU92717I2 (fr) 2015-11-24
PT1409467E (pt) 2012-10-24
BRPI0211379B1 (pt) 2018-02-14
DK1409467T3 (da) 2012-07-16

Similar Documents

Publication Publication Date Title
FR15C0036I1 (enExample)
ATE211732T1 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
NZ329532A (en) Diazepino-indoles as phosphodiesterase iv inhibitors
WO1996013259A3 (en) Method and compositions for inhibiting protein kinases
MXPA03011329A (es) Antiinfecciosos novedosos.
NO932870D0 (no) Ny fremgangsmaate for fremstilling av 9-amino-6-demetyl-6-deoksyetracykliner
PT1155015E (pt) Processo para a preparação de (e)-(6-¬2-¬4-(4-fluorofenil)-6- isopropil-2-¬metil(metilsulfonil)amino pirimidin-5-il vinil(4r,6s)-2,2-dimetil¬1,3 dioxan-4-il)acetato de terc-butilo
AU2002348261A1 (en) Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
AU2003248647A1 (en) Stereoselective synthesis of 1,2-disubstituted cycloalkyls
PL367774A1 (en) Synthesis and intermediates
AP9901698A0 (en) Novel process.
WO2005037780A3 (de) Amidomethyl-substituierte 2-(4-sulfonilamino)-3-hidroxy-3,4-dihydro-2h-chromen-6-yl-derivate, verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
BG104073A (en) Method for preparing alkyloxy furanone derivatives, compounds obtained by said method and use of said compounds
NZ535169A (en) Process for making chiral 1,4-disubstituted piperazines
WO2002053537A8 (en) Process for preparing (±) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
EP1375489A4 (en) MEDICINAL PREPARATION CONTAINING A 1,3-THIAZINE DERIVATIVE
MXPA04003086A (es) Proceso para sintesis estereoselectiva de 2-hidroximetil-cromanos.
PL332594A1 (en) Novel derivatives of pentaerythrite, their production and application as well as intermediate compounds for synthesising them
SI1151130T1 (en) Coenzyme useful for the synthesis of l-carnitine
AU2002222087A1 (en) Cyclizing method for synthesis of compounds derived from pyrrolidine
NO20030876D0 (no) Fremgangsmåte for racemisering av 1-benzyl-4-(4-fluorfenyl)-3- hydroksymetyl-1,2,3,6-tetrahydropyridin for bruk som mellomprodukt i syntese avparoxetin
AU2001282744A1 (en) Process for asymmetric synthesis of substituted 1,4-dihydropyridines
YU40599A (sh) Mikrobna biotransformacija
GB9811297D0 (en) Process for the synthesis of carbapenem intermediates, and compounds produced
GB9806031D0 (en) Process for the synthesis of carbapenem intermediates, and compounds produced